For Investors

2017 was an important year of transition for RepliCel shareholders. The company delivered its first complete set of phase 1 human clinical data, the first fully functional prototypes of its dermal injector, and commenced negotiations on a second major international co-development and licensing partnership in Asia.

In 2018, RepliCel announced the successful completion of a major investment, co-development, and licensing agreement with YOFOTO focused on the commercialization of the tendon, skin, and injector technologies in Greater China.

In 2019, RepliCel's partners, YOFOTO, completed construction and validation of its new development and manufacturing facility in China to support final technology transfer and the launch of clinical programs there. RepliCel also, re-initiated its First-in-Japan Strategy focused on early commercialization of its skin, tendon, and injector products in Japan.

In 2020, RepliCel ordered production of its first batch of commercial-grade dermal injectors to use in the function and clinical testing needed to obtain marketing approvals. Also, clinical data from the second clinical study of RCH-01 was published demonstrating statistically significant clinical resutls in men and women with advanced stages of hair loss due to androgenic alopecia.

2021 promises to be seminal year in RepliCel’s maturity with expected commercial launch of its injector product launch and the potential launch of four new clinical studies – two in China and two in Japan – related to tendon regeneration and skin rejuvenation.

Here you can keep up-to-date with our share price, upcoming events, and latest presentations. We invite you to sign up for our email alerts and welcome any questions you may have.

REPCF Market Data